Takeda Pharmaceutical Granted FDA Approval for LIVTENCITY for Post-Transplant Cytomegalovirus On November 23, 2021 Takeda Pharmaceutical Co Ltd (TAK) announced that the U.S. FDA has approved LIVTENCITY™ (maribavir) for adults and pediatric patients (12 years of age or older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or …

Mirum Pharmaceuticals Inc Mirum Pharmaceuticals Inc (MIRM) is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Maralixibat, is Mirum Pharmaceuticals lead product candidate. The product is an investigational oral drug in development for the following conditions:   Alagille syndrome (ALGS) Progressive familial intrahepatic . . . This content is for paid subscribers. …

Ovid Therapeutics & Takeda Announce Agreement for Soticlestat Ovid Pharmaceuticals is eligible to receive up to $856M in payments, including a $196M upfront payment, regulatory and commercial milestone payments and tiered double-digit royalties on product sales Potential first-in-class therapy reduced seizure frequency in children with Dravet syndrome and Lennox-Gastaut syndrome in Phase 2 ELEKTRA study Original 2017 collaboration between Ovid and Takeda to conclude; Ovid …

Exelixis: FDA Approval for Cabometyx in Combination with Opdivo  Exelixis (EXEL) announced that the United States FDA has approved CABOMETYX (cabozantinib) in combination with OPDIVO® (nivolumab) as a first-line treatment for patients with advanced renal cell carcinoma (RCC). RCC is among the 10 most frequently diagnosed cancers in the U.S. annually. Dr. Toni Choueiri, Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute and The …

Moderna Inc Late August Announcements  On August 28, 2020 Moderna Inc (MRNA) issued a press release confirming that the Company is engaged in discussions with the Ministry of Health, Labor and Welfare of Japan (MHLW) to potentially purchase 40 million or more doses of its COVID-19 vaccine candidate, mRNA-1273. Under the terms of this arrangement the . . . This content is for paid subscribers. …

CiRA, Takeda & T-CiRA Less than five years ago the Center for iPS Cell Research and Application (CiRA)1 at Kyoto University and Takeda Pharmaceutical (TAK)2 established a research program. Today, Takeda and CiRA announced that induced pluripotent stem cell-derived chimeric antigen receptor (CAR) T-cell therapy (iCART . . . This content is for paid subscribers. Please click here to subscribe or here to log in.